Overexpression of EIF5A2 in upper urinary tract urothelial carcinoma is a new independent prognostic marker of survival

To study the expression of EIF5A2 in urinary tract urothelial carcinoma and its clinicopathological features and prognosis. EIF5A2 expression was detected via immunohistochemistry in 101 patients. Kaplan-Meier analysis showed that the EIF5A2 low expression group had significantly longer overall survival (OS; p < 0.001) and progression-free survival (PFS; p < 0.001) than the EIF5A2 high expression group. The high expression of EIF5A2 significantly predict poor OS and PFS in the subset patients (p < 0.05). EIF5A2 was an independent prognostic factor for OS and PFS (p = 0.003 and p = 0.001). The established nomogram model and its calibration curve predicted the probability of survival accurately. EIF5A2 is a potential molecular marker of poor prognosis in urinary tract urothelial carcinoma.